Serum GP73 for diagnosing decompensated cirrhosis in population with chronic HBV infections
10.3760/cma.j.issn.1003-9279.2014.02.003
- VernacularTitle:血清GP73对HBV相关失代偿性肝硬化的诊断价值
- Author:
Qingling ZHAI
1
;
Yubo HUANG
;
Xiaohua HAO
;
Hongmin LI
;
Hui REN
;
Hongshan WEI
Author Information
1. 首都医科大学附属北京友谊医院
- Keywords:
Golgi apparatus,Hepatitis B,chronic;
Hepatitis B virus;
Liver cirrhosis;
Liver neoplasms
- From:
Chinese Journal of Experimental and Clinical Virology
2014;28(2):85-86
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the role of serum GP73 for diagnosing decompensated cirrhosis in population with chronic HBV infections.Methods The present study included three populations:200 patients with chronic HBV infections and receiving liver biopsy; 200 patients with decompensated cirrhosis;and 200 patients with hepatocellular carcinoma.All patients were HBsAg-positive over six months.Results Comparing with those in the patients with chronic hepatitis B (67.38 ±57.45 ng/ml),the serum GP73 levels in cirrhosis patients (221.9 ± 108.5 ng/ml) and HCC patients (152.4 ± 102.7 ng/ml) were significantly increased.Taken the population with chronic hepatitis B as "control group",the patients with decompensated cirrhosis as "patients group",the area of ROC analysis was 0.91 (95％ CI:0.88-0.94) (P ＜0.0001).Set the cut-off value at 150 ng/ml,the diagnosing sensitivity and specificity were 72.5％ and 93.5％,respectively.Conclusion For patients with chronic HBV infections and a higher GP73 levels,decompensated cirrhosis should be considered,except diagnosis of hepatocellular carcinoma.
